24124-59-2

Basic information

• Product Name: 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene
• Synonyms: 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene;METHYLENE BIS(TOLUENE-4-SULFONATE);Methylene Bis-tosylate;methylene ditosylate
• CAS NO: 24124-59-2
• Molecular Formula: C₁₅H₁₆O₆S₂
• Molecular Weight: 356.42
• Mol File: 24124-59-2.mol

Chemical Properties

• Melting Point: 116-118°C
• Boiling Point: 523.2°Cat760mmHg
• Flash Point: 270.2°C
• Appearance: /
• Density: 1.356g/cm³
• Vapor Pressure: 1.61E-10mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene(24124-59-2)
• EPA Substance Registry System: 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene(24124-59-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 24124-59-2(Hazardous Substances Data)

Usage

Uses

Given the provided materials, there are no specific applications listed for 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene. However, based on its chemical structure and the nature of similar compounds, potential uses could be hypothesized in the following industries:
Used in Pharmaceutical Industry:
1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene could be used as a pharmaceutical intermediate for the synthesis of drugs with specific therapeutic effects. Its complex structure and sulfonyl groups may allow it to interact with biological targets, potentially leading to the development of new medications.
Used in Chemical Industry:
In the chemical industry, 1-methyl-4-[(4-methylphenyl)sulfonyloxymethoxysulfonyl]benzene might serve as a reactant or catalyst in various chemical processes. Its reactivity and functional groups could be harnessed to facilitate specific chemical transformations or to improve the efficiency of industrial processes.

InChI:InChI=1/C15H16O6S2/c1-12-3-7-14(8-4-12)22(16,17)20-11-21-23(18,19)15-9-5-13(2)6-10-15/h3-10H,11H2,1-2H3

Upstream product

• 75-11-6 diiodomethane 
• 16836-95-6 silver(I) 4-methylbenzenesulfonate 
• 593-71-5 Chloroiodomethane 
• 80-48-8 methyl p-toluene sulfonate 
• 104-15-4 toluene-4-sulfonic acid 
• 74-88-4 methyl iodide 
• 74-95-3 1,1-dibromomethane 

Downstream Products

• 91894-66-5 4,6-ditosylperhydro-1,4,6-oxadiazonine 
• 91-20-3 naphthalene 
• 24973-91-9 1H-Cyclobutanaphthalene 
• 117184-50-6 chloromethyl tosylate 
• 117184-51-7 bromomethyl 4-toluenesulfonate 
• 117184-52-8 iodomethyl 4-methylbenzenesulfonate 
• 121424-77-9 7,11,15,28-tetrabromo-1,21,23,25-tetrakis(2-phenylethyl)-2,20:3,19-dimetheno-1H,21H,23H,25H-bis[1,3]dioxocino[5,4-i:5',4'-i']benzo[1,2-d:5,4-d']bis[1,3]benzodioxocin 
• 114435-86-8 fluoromethyl 4-methylbenzenesulfonate 
• 113426-16-7 [18F]fluoromethylene toluene-4-sulfonate 
• 835605-47-5 [18F]FCH 
• 1596347-54-4 di-tert-butyl (p-toluenesulfonylmethyl) phosphate 
• 1638151-15-1 C₂₈H₂₅N₅O₅S 
• 455-16-3 p-toluenesulfonyl fluoride 

Relevant articles and documents

Mild Darzens Annulations for the Assembly of Trifluoromethylthiolated (SCF3) Aziridine and Cyclopropane Structures

We report mild new annulation approaches to trisubstituted trifluoromethylthiolated (SCF3) aziridines and cyclopropanes via Darzens inspired protocols. The products of these anionic annulations, rarely studied previously, possess attractive features rendering them valuable building blocks for synthesis platforms. In this study, trisubstituted acetophenone nucleophiles bearing SCF3 and bromine substituents in their α position were shown to undergo [2 + 1] annulations with vinyl ketones and tosyl-protected imines under mild reaction conditions.

HPLC-free: In situ 18F-fluoromethylation of bioactive molecules by azidation and MTBD scavenging

Sequential usage of azide and MTBD, which generates pure [18F]fluoromethyl tosylate and scavenges unreacted desmethyl precursors, provided an efficient HPLC-free strategy for the radiosynthesis of 18F-fluoromethylated compounds with

A practical microwave method for the synthesis of fluoromethy 4-methylbenzenesulfonate in tert-amyl alcohol

Fluorine substitution is an established tool in medicinal chemistry to favourably alter the molecular properties of a lead compound of interest. However, gaps still exist in the library of synthetic methods for accessing certain fluorine-substituted motifs. One such area is the fluoromethyl group, particularly when required in a fluoroalkylating capacity. The cold fluorination of methylene ditosylate is under evaluated in the literature, often proceeding with low yields or harsh conditions. This report describes a novel microwave method for the rapid nucleophilic fluorination of methylene ditosylate using inexpensive reagents in good isolated yield (65%).

Synthesis and evaluation of [18F]-fluoromethyl triphenylphosphonium cation as a novel mitochondria-specific positron emission tomography tracer

We developed a radiosynthesis of the voltage sensitive tracer [18F]-fluoromethyltriphenylphosphonium cation ([18F]-FTPMP), giving high yield (30-34%, decay-corrected), radiochemical purity (>99%) and specific activity (about 760 GBq/

11C- and 18F-Labeled Radioligands for P-Glycoprotein Imaging by Positron Emission Tomography

P-Glycoprotein (P-gp) is an efflux transporter widely expressed at the human blood-brain barrier. It is involved in xenobiotics efflux and in onset and progression of neurodegenerative disorders. For these reasons, there is great interest in the assessmen

Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability

Abstract In recent years, mGlu4 has received great attention and research effort because of the potential benefits of mGlu4 activation in treating numerous brain disorders, such as Parkinson's disease (PD). Many positive allosteric m

Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: Synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism

Based on the potent phosphodiesterase 10 A (PDE10A) inhibitor PQ-10, we synthesized 32 derivatives to determine relationships between their molecular structure and binding properties. Their roles as potential positron emission tomography (PET) ligands were evaluated, as well as their inhibitory potency toward PDE10A and other PDEs, and their metabolic stability was determined in vitro. According to our findings, halo-alkyl substituents at position 2 of the quinazoline moiety and/or halo-alkyloxy substituents at positions 6 or 7 affect not only the compounds′ affinity, but also their selectivity toward PDE10A. As a result of substituting the methoxy group for a monofluoroethoxy or difluoroethoxy group at position 6 of the quinazoline ring, the selectivity for PDE10A over PDE3A increased. The same result was obtained by 6,7-difluoride substitution on the quinoxaline moiety. Finally, fluorinated compounds (R)-7-(fluoromethoxy)-6-methoxy-4-(3-(quinoxaline-2-yloxy)pyrrolidine-1-yl) quinazoline (16 a), 19 a-d, (R)-tert-butyl-3-(6-fluoroquinoxalin-2-yloxy) pyrrolidine-1-carboxylate (29), and 35 (IC50 PDE10A 11-65 nM) showed the highest inhibitory potential. Further, fluoroethoxy substitution at position 7 of the quinazoline ring improved metabolic stability over that of the lead structure PQ-10. Fluor your health: Phosphodiesterase 10 A (PDE10A) has emerged as an attractive target for the development of 18F-labelled brain imaging agents for positron emission tomography. A series of fluorinated dialkoxybiaryl compounds were synthesized and evaluated as PDE10A inhibitors, assisted by QSAR docking studies. The 7-fluoromethoxy derivative appears to be a promising candidate for further development.

2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention o

NOVEL PRECURSOR

Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal, ovarian, endomet

NOVEL RADIOTRACER

Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal, ovarian, endomet